Pharming Group (PHAR) reported a Q2 earnings Thursday of $0.002 per diluted share, compared with $0.006 a year earlier.

Three analysts polled by FactSet expected $0.01.

Revenue for the quarter ended June 30 was $90.2 million, down from $93.2 million a year earlier.

Four analysts polled by FactSet expected $99.5 million.

The company updated its full-year 2026 revenue guidance to $375 million to $395 million, compared with its prior guidance of $405 million to $425 million. Analysts polled by FactSet are expecting $404 million.